Renal transplantation is the treatment of choice for renal transplantation. end-stage renal failure. However, post-transplant osteo-Background. Bisphosphonates can prevent bone mineral dystrophy is a major problem, especially in the first density loss after renal transplantation, but their effect on tramonths after transplantation, because about 10% of bone becular mineralization and bone morphology, two key factors density is lost during this period [1]. The bone disease is of bone stability, remains unknown.
ease, and long-term use of loop diuretics contribute to Results. Trabecular calcium content increased significantly bone loss [3] . In addition, the main cause of terminal in the zoledronic acid group, but remained unchanged in the placebo group. BMD at femoral neck showed no change in renal failure is diabetic nephropathy, and diabetes itself the zoledronic acid group, but decreased in the placebo group. causes osteoporosis [4] . Some of these factors cease after BMD of the lumbar spine was increased in the zoledronic acid successful renal transplantation, but new, and even worse, group without change in the placebo group. High-turnover causes of osteodystrophy arise. Among these are high bone disease resolved similarly in both groups, as evidenced by a significant decrease of eroded bone surface, osteoclast steroid doses in the immediate post-transplant period, and osteoblast surface. Serologic markers of bone formation calcineurin antagonist type of immunosuppression, renal and resorption were significantly lower in zoledronic acidtubular impairment of calcium and phosphorus reabtreated patients throughout the study. Kidney transplant funcsorption, and the aggravation of the metabolic disturtion was stable after zoledronic acid therapy. bances in diabetic patients.
Conclusions. Our results show that administration of zoledronic acid improves the calcium content of cancellous bone Early, as well as late, post-transplant bone loss has after kidney transplantation. The beneficial effect of bisphosbeen studied thoroughly by densitometry and bone morphonate therapy is further evidenced by an increase of lumbar phometry in children and adults [5, 6] . Changes in bone spine BMD, and stabilization of femur BMD. architecture, however, have been investigated only in two small studies. Julian et al [1] reported sequential changes in bone morphology in 20 young patients without diabetes and major comorbidity, and more than one half of these patients had been transplanted preemption periods [1] . Briner et al [7] investigated the bonesparing effect of a low-dose steroid regimen in 20 patients  2003 by the International Society of Nephrology with sequential transiliac crest biopsies and found an METHODS increase in cancellous bone volume, but no resolution Patients of metabolic bone abnormalities 2 years after trans-We consecutively recruited 28 adult hemodialysis paplantation.
tients, who received their first or second cadaveric renal Several investigators conducted prospective treatment allograft. Patients were enrolled independently of the studies in patients with post-transplant osteodystrophy, cause of renal failure, time on renal replacement therapy, but used only densitometry or biochemical markers of or bone disease. Hemodialysis was performed in all pabone turnover as a treatment outcome variable. Densitients according to the Dialysis Outcome Quality Initiatometry and biochemical markers, however, are not suittive (DOQI) guidelines [22] . Out of the 28 patients enable to uncover morphologic-architectural changes and rolled, 24 received 0.25 to 0.5 g 1,25 (OH) 2 vitamin D 3 per day. Patients who had had previous or current are only of moderate value to discriminate between the treatment with either calcitonin or bisphosphonates, or various causes of renal osteodystrophy and to define with hypocalcemia, were excluded from the study. patients at risk for fractures [8] [9] [10] . Therefore, more sensitive methods of bone mineralization and bone archi-Procedures tecture measurements such as bone mineralization den-
The study protocol was approved by the Institutional sity distribution measurement (BMDD) (i.e., the degree Review Board and each patient provided informed conof trabecular calcium content in a given bone specimen sent. Twenty of the 28 enrolled patients, who met the and bone morphometry) are necessary to guide therainclusion criteria of serum creatinine below 2 mg/dL peutic intervention and evaluate treatment success. The within 2 weeks after transplantation, and a representadiverse pathophysiologic entities of the skeletal changes tive bone biopsy core obtained during the transplant allow discrimination between morphologically distinctly procedure, were randomly assigned to an intravenous different types of renal osteodystrophies [8, 11] . The infusion of 4 mg zoledronic acid or placebo in 250 mL mineralization density and distribution can be evaluated saline over 15 minutes. Eight of the 28 patients did not on bone biopsy specimen by quantitative backscattered meet the study inclusion criteria. Two patients died electron imaging, a method that has been proved to within the first week after transplantation due to cardiac be sensitive in the detection of small changes in the arrest, four patients had a serum creatinine above 2 mineralization pattern due to bisphosphonate treatment mg/dL 2 weeks after transplantation, the bone biopsy of patients and in animal studies [12] [13] [14] . Furthermore, specimen was not adequate in one patient, and one pa-BMDD allows discrimination between changes in bone tient withdrew consent before the first zoledronic acid/ volume and the degree of mineralization, which is not placebo infusion. possible with conventional x-ray densitometry. Hence, A second infusion at the same dose was administered 3 months later. Therapy and randomization were supit is possible that x-ray densitometry reveals high bone plied by Novartis (Basel, Switzerland). All patients remass in regions of reduced bone matrix mineralization ceived 1000 mg of daily calcium citrate, but no vitamin and thus impaired mechanical stability. D supplementation (Maxi-Kalz, Asta Medica, Vienna, The new bisphosphonate zoledronic acid (Zometa, Austria). The immunosuppressive regimen consisted of Novartis, Basel, Switzerland) potently inhibits osteoclasmethylprednisolone, mycophenolate mofetil, and cyclotic bone resorption and has been shown to prevent osteosporine. Two patients in the placebo group and one paporosis associated with estrogen deficiency, and halt protient in the zoledronic acid group received tacrolimus gression of osteolysis [15] [16] [17] . Zoledronic acid has not instead of cyclosporine. been investigated for corticosteroid-induced osteoporo-Bone histology and histomorphometry were persis, but convincing data are available for other bisphosformed on transcortical bone biopsies obtained from the phonates, such as etidronate [18] . Besides the reduction iliac crest during and 6 months after kidney transplantaof bone turnover, zoledronic acid has been shown to tion as described by Bordier, Miravet, and Hioco [23], directly decrease type II collagen degradation in patients using the Meunier Bone Biopsy device (luminal diameter with Paget's disease [19] . Zoledronic acid is two to three 7 mm ϭ 0.28 inch; Groupe Lé pine, Lyon, France). Due orders of magnitude more potent than pamidronate in to the design of the study (cadaver kidney transplantabone resorption assays, but showed a threefold greater tion), the time point of transplantation was unknown renal tolerability [20, 21] . and, thus, tetracycline labeling was not feasible. The So far, no controlled study on the effect of bisphosphospecimens were then undecalcified embedded in plastic nate therapy on bone morphology and mineralization and cut into 5 m thick sections. After standard staining, density distribution for the prevention of post-transplant histologic analysis was performed by one pathologist (G.D.), who was blinded for the clinical and biochemical osteopathy exists. status, as well as the randomization group of the patients.
Blood samples for biochemical bone markers were drawn immediately before transplantation and monthly Renal osteodystrophy was classified according the Delling criteria, as reported previously [11] . By these criteria during follow up in all twenty patients. Bone alkalinephosphatase was measured by immunosorbent enzyme-three different groups of renal osteodystrophy are identified (types I, II, and III). If compared to the classification linked assay (ELISA), osteocalcin, intact parathyroid (iPTH) and type I collagen peptides (crosslaps) by elec-of Malluche and Faugere [24] , renal osteodystrophy type II would equal osteomalacic low-turnover bone disease tro-chemiluminiscence and 1,25(OH) 2 D3 by a radioimmuno assay. and renal osteodystrophy type III would equal predominant hyperparathyroid, or high-turnover bone disease.
Statistical analysis Mixed uremic osteodystrophy would spread over both groups depending of whether osteoidosis (renal osteo-All results are expressed as mean Ϯ SE or median and range when appropriate. Sample size calculation dystrophy type II) or osteoidosis and fibroosteoclasia (renal osteodystropy type III) predominates. Renal os-revealed a minimum of 10 patients in each group to detect a Ͼ2% difference in mean BMDD giving an ␣ of teodystrophy type I is mainly characterized by fibroosteoclasia and bone marrow fibrosis and was not present Ͻ0.05 and ␤ Ն 0.8. We estimated that 80% of patients would meet the inclusion criteria and post-randomiza-in any of our patients. Three-dimensional morphometric analysis was carried out as described previously [11] .
tion discontinuation rate would be 10%. Either the two-tailed Student t test for paired data or According to Parfitt et al [25] , the following parameters were evaluated: trabecular bone volume and osteoid vol-the non-parametric Wilcoxon sign rank test was used for differences in the same group at different time points. ume, both expressed as the percentage of tissue volume; osteoid surface, expressed as the percentage of trabecu-
The Student t test for unpaired data or the Mann-Whitney U test were used for differences between the groups. lar bone surface; osteoblast surface; expressed as the osteoid surface covered with osteoblasts, and as percent-Bonferroni-Holm correction was used for multiple comage of trabecular bone surface; osteoclast surface, exparisons. To evaluate the difference in trabecular calpressed as the osteoid surface covered with osteoclasts, cium concentration between the zoledronic acid and plaand as the percentage of trabecular bone surface; and cebo group at 6 months, a multiple linear regression eroded surface, expressed as percentage of trabecular model adjusted for baseline differences was used. A P bone surface. value Ͻ0.05 was considered statistically significant. Measurements of BMDD were performed using a quantitative backscattered electron imaging method de-RESULTS scribed previously [12, 14] . This method is based on the Baseline characteristics were similar in both treatment phenomenon that the backscattering coefficient of the groups, with the exception of BMDD and osteoclast electrons is dependent on the atomic number of the tarsurface. Six patients withdrew their consent for a second get material. In the case of bone tissue the backscattered biopsy, thus only 14 bone biopsies were performed at electron signal is directly proportional to the mineral the end of the study. One of the second bone biopsy content (calcium content) of the tissue. BMDD was specimens contained mainly callous bone, possibly after quantified by the BMDD-parameter Ca mean , describing a foregoing microtrauma and was not suited for further the weighted mean calcium (Ca) concentration of the analysis. In summary, a total of seven (pre-and post-) imaged bone area. The full width at half maximum of specimens were available from the zoledronic acid group, the peak is a measure of the homogeneity of the distribuand six (pre-and post-) specimens from the placebo tion. All measurements were blinded for quantitated group. Therefore, baseline and 6 months' data on bone backscattered electron imaging, histomorphometric, and morphology and BMDD are given only for these 13 biochemical analysis.
patients. The cumulative dose of methylprednisolone in Bone mineral density measurements (BMD) were perthe first 6 months after transplantation averaged 2.9 Ϯ formed with dual-energy x-ray absorptiometry and a 0.4 g in the 10 placebo patients and 3.0 Ϯ 0.8 g in the QDR-4500 scanner (Hologic, Waltham, MA, USA), using 10 zoledronic acid-treated patients. In the six placebo the manufacturer's recommended standard procedures and seven zoledronic acid patients with complete bone for the posteroanterior lumbar spine at L1-L4, and for biopsy studies, the methylprednisolone doses were 2.4 Ϯ the proximal femur at the femoral neck, trochanter, in-0.7 and 2.7 Ϯ 0.6 g respectively. tertrochanteric region, total region, and Ward's triangle.
Distribution of renal osteodystrophy was similar in The projectional BMD values were given in grams per both groups at baseline (Table 1) . Histomorphologic feacentimeter squared, and the individual patient's results tures of high-turnover bone disease diminished within 6 were expressed as z scores and t scores. The diagnostic months after transplantation as evidenced by a signifibone-mass threshold for defining osteoporosis in individuals without fractures was set at a t score less than -2.5. cant decline of eroded surface, osteoblast surface, and osteoclast surface in both groups (Table 2) . Although Osteocalcin, type I collagen peptides (crosslaps), and mean osteoblast surface and osteoclast surface was com-iPTH decreased rapidly after transplantation. Osteocalparable between the groups, osteoid surface had incin and type I collagen peptides (crosslaps), indicators of creased significantly in patients receiving zoledronic acid increased bone formation and resorption, respectively, but remained unchanged in untreated patients (Table  were significantly lower in patients receiving zoledronic 2). No biochemical or clinical evidence of osteomalacia ( Fig. 1) . Intact PTH levels were slightly higher in the could be detected in the zoledronic acid-treated patients. placebo group at transplantation, but similar in both Adynamic bone disease in the zoledronic patients could groups during monthly follow-up. Alkaline phosphatase, be ruled out because unlike osteomalacia, the histopaas a marker for osteoblast activity, was slightly but nonthology of adynamic bone disease does not include an significantly, higher in the placebo group and did not increase in osteoid formation.
differ from baseline values in either group. 1,25(OH) 2 There was a significant difference of mean trabecular vitamin D 3 plasma levels increased as expected in both calcification (Ca mean ) between both groups at baseline, groups after transplantation (placebo, 10 Ϯ 3 vs. 27 Ϯ 9 with a higher concentration in patients who were going pg/mL, P Ͻ 0.05; and zoledronic acid, 8 Ϯ 3 vs. 13 Ϯ 10 to receive zoledronic acid. However, at the end of pg/mL, P ϭ NS). Renal function did not change after the study, trabecular calcium content had only increased zoledronic acid infusion. Serum creatinine baseline valin zoledronic acid-treated patients and remained unues and values at 6 months were similar within the changed in the placebo group (Table 2) . Multiple linear groups, as well as between the groups (placebo vs. zoleregression revealed a significant correlation between dronic acid 2 weeks after transplantation, 1.4 Ϯ 0.9 vs. baseline values and Ca mean at 6 months (P ϭ 0.03). When 1.5 Ϯ 0.6 mg/dL; 6 months after transplantation, 1.5 Ϯ adjusted for baseline differences in Ca mean between the 0.1 vs. 1.4 Ϯ 0.1 mg/dL). No differences between the zoledronic acid and placebo group, the difference at 6 groups could be observed in the baseline values of calmonths failed to reach statistical significance (P ϭ 0.08). cium (placebo, 10 Ϯ 0.4 vs. zoledronic acid, 9.2 Ϯ 0.4 The full width at half maximum of the peak did not show mg/dL) and phosphorus (placebo, 6.2 Ϯ 0.6 vs. zoleany significant difference between the zoledronic aciddronic acid, 5.9 Ϯ 0.6 mg/dL). The respective values at treated and non-treated group at baseline and at 6 6 months were calcium (placebo, 10 Ϯ 0.8 vs. zoledronic months, suggesting a homogenous distribution of trabecacid, 9.6 Ϯ 0.4 mg/dL) and phosphorus (placebo, 2.8 Ϯ ular calcification. 0.3 vs. zoledronic acid, 2.5 Ϯ 0.3 mg/dL). Dual-energy x-ray absorptiometry measurements were available from all patients at transplantation and after DISCUSSION 6 months. Mineral content of lumbar spine (g/cm 2 ) and
This study demonstrates that two intravenous infuz score improved significantly in patients receiving zolesions of the bisphosphonate zoledronic acid prevented dronic acid. In contrast, in placebo-treated patients, post-transplant bone loss by increasing average trabecu-BMD of lumbar spine deteriorated significantly (Table  lar calcium concentration (Ca mean ) in renal allograft recip-2). Dual-energy x-ray absorptiometry of the femur reients in the first 6 months after successful transplantation. vealed a significant decrease of BMD of the femoral The weight fraction of mean trabecular calcium inneck, the Ward's triangle, and trochanter in the placebo creased by 2% in the zoledronic acid group, but was group, but not in patients receiving zoledronic acid.
unchanged in the placebo group. Between group differ-BMD of the intertrochanteric region remained unchanged in both groups (Table 2) . ences at 6 months were not statistically significant after adjustment of the multiple linear regression model for thus argues strongly against osteomalacia in the zolebaseline differences in Ca mean . The likeliest explanation dronic acid group. Adynamic bone disease could be exfor the mean difference in baseline Ca mean of 0.3 weight pelled by the increase of osteoid in the zoledronic acid % after randomization is the relatively small sample size group. Markers of high turnover bone disease such as of the study. The increase in Ca mean from 21.8 to 22.2 osteoblast and osteoclast surface and eroded surface imweight % in the zoledronic acid group seems low, but proved significantly within the first 6 months after engiven the small intra-and interassay variations of 0.27 graftment in both patient groups, which can be attributed and 0.30%, respectively, are statistically significant. Furto the reduction of the secondary hyperparathyroidism thermore, zoledronic acid treatment led to an increase after successful renal transplantation in both groups. of Ca mean close to the reference range, which was deter-Our findings support the hypothesis of investigators mined post-mortem in 20 individuals of wide age range from previous studies, that third-generation bisphosphodistribution without bone disease, who died in accidents nates lead to an increase of cancellous bone formation [12] . Osteoid surface increased by 39% in the zoledronic [31, 32] . This could so far only be measured indirectly acid group, but was unchanged in the placebo group.
by dual-energy x-ray absorptiometry of the cancellous Furthermore, BMD of the lumbar spine increased by vertebrae in comparison to the dual-energy x-ray absorp-31% in the bisphosphonate group, but deteriorated furtiometry readings of the cortical femur neck. However, ther by 38% (z score) in the placebo group, although the trabecular mineralization and architecture are more all patients were treated concomitantly with 1000 mg important for the stability and performance of the bone calcium citrate daily. than cortical mineralization [34] . To further analyze the It has been shown previously that vitamin D, calcitoinfluence of zoledronic acid on cancellous bone, we used nin, estrogen, or testosterone supplementation is ineffecseveral methods. Besides dual-energy x-ray absorptiometive in preventing post-transplant bone loss [26] [27] [28] [29] [30] .
try, which, due the high absorption of the cortical layer, Older generation bisphosphonates could not prevent is, in particular, insufficient in femoral cancellous bone early post-transplant bone loss, but exhibited benefits density measurement, we additionally determined minfrom 1 year on in preventing further deterioration of eralization density distribution and morphometry of bone existing bone disease [26, 27] . Newer generation bisphosbiopsies. The main finding in the current investigation phonates, such as pamidronate and ibandronate, are was the significant increase of Ca mean , a very sensitive more potent than first-generation bisphosphonates on measure of trabecular mineralization with low interindian equimolar basis and can prevent the loss in BMD after vidual variation of results [12] . This result of increased transplantation [31, 32] . Similar results were obtained in Ca mean is in accordance with previous studies on human the present study with zoledronic acid. The placebo and animal bone bisphosphonate treatment [13, 14] . The group patients experienced a reduction in cancellous measured increase of calcium content was confirmed by bone density, and zoledronic acid-treated patients exhibsignificantly lower serologic markers specific for bone ited an increase in lumbar spine mineral density in dualformation (osteocalcin) and increased bone resorption energy x-ray absorptiometry studies. However, an in-[type I collagen peptides (crosslaps)] in treated patients. crease in densitometry scores does not necessarily mean Biochemical markers of high-turnover osteopathy, such higher bone stability. Logistic regression analysis showed as iPTH, improved in both treatment groups within the only a weak association between BMD and fracture risk.
first 6 months after transplantation, mirroring the histo-Per z score unit increase in spine BMD, the odds ratio morphologic changes that result from adequate renal of developing a fracture within a median of 5 years was transplant function. 1.57 (1.04 to 2.37, 95% CI) in nontransplanted patients [33] . One of the main determinants of bone strength is bone architecture [34] . Because randomized studies of CONCLUSION post-transplant osteopathy in renal patients with fracture
In conclusion, this is the first study to show that post rate as end point are unlikely to be conducted, treatment transplant administration of zoledronic acid not only consuccess with regards to changes in bone architecture (miferred an increase of bone mineralization but, that despite cromorphology) can only be evaluated by quantitative the use of high steroid doses, trabecular calcium content histomorphometry of bone biopsy cores. The present increased and cancellous bone could be stabilized. study is the first to show that the new-generation bisphosphonate zoledronic acid led to an increase of osteoid ACKNOWLEDGMENTS surface. Osteomalacia was ruled out by biochemical parameters of bone turnover, but could not be excluded suggests an increase in trabecular mineralization and
